Glaucoma is a leading cause of worldwide irreversible visual impairment and blindness and is a clinically and genetically heterogenous group of optic neuropathies. Specific mutations in the myocilin (MYOC ) gene cause primary open angle glaucoma (POAG) with varying age-of-onset and degree of severity. We show a mutation-dependent, gain-of-function association between human myocilin and the peroxisomal targeting signal type 1 receptor (PTS1R). There was correlation between the glaucoma phenotype and the specific MYOC mutations, with the more severe early-onset POAG mutations having a higher degree of association with PTS1R. Expression of human myocilin glaucomatous mutations in mouse eyes causes elevated intraocular pressure, which is a major phenotype of MYOC glaucoma. This is the first demonstration of a disease resulting from mutation-induced exposure of a cryptic signaling site that causes mislocalization of mutant protein to peroxisomes and the first disease-gene-based animal model of human POAG.
INTRODUCTION
Myocilin (MYOC ) was the first primary open angle glaucoma (POAG) gene identified and is the most common known genetic cause of glaucoma (1) . MYOC maps to the GLC1A locus on chromosome 1q24 and encodes a 504 amino acid protein. Numerous missense and nonsense mutations in MYOC have been shown to be causative for POAG (1) and represent 2 -4% (2) of worldwide POAG. Elevated intraocular pressure (IOP) is a major risk factor for the development and progression of glaucoma, and MYOC glaucoma is associated with elevated IOP. There is a phenotypic correlation of specific MYOC mutations with the age-of-onset, degree of elevated IOP and severity of POAG (3, 4) . For example, the Y437H, G364V and Q368X mutations have a mean age of diagnosis of 20, 34 and 59 years, with the highest recorded IOP of 44, 36 and 30 mmHg, respectively (4) .
Myocilin is a secreted glycoprotein from the trabecular meshwork (TM), a tissue responsible for aqueous humor outflow and therefore the level of IOP. Several lines of evidence indicate that mutant myocilin causes glaucoma by the gain of a deleterious function within specific ocular tissues such as the TM. Patients who are deficient in myocilin protein either by hemizygous interstitial deletion of MYOC on 1q24-q26 (5) or by heterozygous or homozygous R46X truncation mutation of MYOC (6) do not necessarily develop POAG. Mice overexpressing wild-type (WT) or mutant mouse MYOC do not develop elevated IOP. Likewise, IOP is not changed in heterozygous or homozygous MYOC knockout mice (7 -9) . Therefore, elimination of human or mouse myocilin protein or overexpression of mouse myocilin is not sufficient to cause POAG. In vitro, glaucomatous MYOC mutations lead to inhibition of myocilin secretion (10) , detergent insolubility (11) and accumulation of mutant myocilin in the endoplasmic reticulum (ER) (12) , further supporting a detrimental role of mutant protein molecules in IOP elevation. In order to better understand the gain-of-function mechanism for mutant myocilin, we identified interacting proteins and the resulting localization of mutant myocilin within TM cells. We found that mutant myocilin interacts with PTS1R leading to co-localization with peroxisomes. PTS1R is a peroxisomal matrix shuttling receptor that recognizes variants of the canonical SKL peroxisomal targeting sequence-1 (PTS1) on the C-terminus of peroxisomal matrix proteins (13) . The homologous context of the PTS1 sequence in a protein has been shown to be crucial to its functionality, but substitutions of the SKL motif such as (S/A/C)(K/H/R)(L/M) are tolerated (14) . The PTS1R tetratricopeptide repeat (TPR) domain is responsible for recognition of the PTS1 motif. Expression of mutant human myocilin in mouse eyes causes elevated IOP, which is associated with the exposure of a cryptic PTS1 site on the mutant molecule.
RESULTS

Identification of PTS1R as a myocilin interacting partner
Yeast two-hybrid assays are used to identify protein -protein interactions by the use of a bait (myocilin) and prey (cDNA library) coupled to a DNA-binding domain (DBD) or activation domain (AD). Interaction of the bait-DBD and prey-AD drives promoter -reporter gene expression and selectivity in yeast. To detect binding partners for wild-type myocilin (WT MYOC), we performed a yeast two-hybrid screen with full-length human myocilin and a human heart cDNA library. We failed to detect any potential interacting partners (data not shown). We then divided myocilin into two domains containing either the Nterminal half (exons 1 -2; aa 1-243) or C-terminal half (exons 2 -3; aa 244-504) (Fig. 1A) .
Analysis with the N-terminal and C-terminal myocilin domains using human heart and TM cell cDNA libraries identified five clones interacting with the C-terminal half, but none with the N-terminal half (Fig. 1B) . All C-terminal interacting clones (A1, A4, A5, B3 and C9) encoded various segments of the peroxisomal targeting signal 1 receptor (PTS1R; RefSeq No. NM_000319.1) (Fig. 1B and C) . All PTS1R clones identified by our yeast two-hybrid screen contained the PTS1 binding domain and encoded two alternative splice variants of PTS1R, a long (PTS1RL) and a short (PTS1RS) form (Fig. 1C ).
PTS1R interacts with the myocilin C-terminus
Mammalian two-hybrid assays are similar in concept to yeast two-hybrid assays and use DBD-coupled bait (myocilin) and AD-coupled prey (PTS1R) to drive promoter-reporter gene ÃÃ represents statistical significance (P , 0.01) versus the negative control group.
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Human Molecular Genetics, 2007, Vol. 16, No. 6 expression (luciferase), but are performed in a mammalian environment rather than yeast. We verified the myocilin -PTS1R interaction using a mammalian two-hybrid assay. Fulllength WT myocilin, N-terminal half WT (aa 1 -367), Cterminal half WT (aa 200 -504), C-terminal half Y437H mutant and C-terminal half S502P mutant myocilin association with PTS1RS were determined by luciferase reporter activity (Fig. 1D ). Full-length and N-terminal half WT myocilin showed control levels of luciferase activity, suggesting a lack of interaction with PTS1R and corroborating the lack of PTS1R interaction seen in the yeast two-hybrid assay. In contrast, the C-terminal half WT myocilin significantly increased luciferase activity (P , 0.01), showing an interaction with PTS1R and confirming the interaction noted in the yeast twohybrid assay. Introduction of the Y437H mutation into C--terminal-half myocilin had similar but no additional effect on luciferase activity. To determine if the predicted PTS1 sequence (SKM 504 ) on the C-terminus of myocilin is involved in the PTS1R interaction, we mutated serine 502 to proline in C-terminal half myocilin, which eliminated the PTS1 signal. The S502P mutant completely abrogated luciferase activity in the mammalian two-hybrid assay.
Myocilin interacts with PTS1R in a mutation-dependent fashion
We used co-immunoprecipitation assays of transfected TM cells to confirm the interaction of PTS1R with mutant myocilin. Myocilin plasmids were co-transfected into human TM cells along with VP16-tagged PTS1R followed by immunoprecipitation of the cell lysate with antibodies directed against either VP16-PTS1R ( Fig. 2A) or myocilin (Fig. 2B) . The immunoprecipitated proteins were subjected to western blotting with anti-myocilin antibody ( Fig. 2A and B ) or anti-PTS1R (Fig. 2B ). The interaction of myocilin with PTS1R varied depending on the particular myocilin mutation. Full-length WT myocilin and K398R (a non disease-causing polymorphism) did not appreciably interact with PTS1R ( Fig. 2A) . In contrast, mutant myocilin interacted with PTS1R either directly or indirectly. The more severe myocilin Y437H and G364V mutants, which contain the PTS1 site, showed the strongest levels of interaction with PTS1R. The Q368X mutation, which lacks the PTS1, did not directly interact with PTS1R. Myocilin is known to form homodimers and multimers via the leucine-zipper domain (Fig. 1A ) in the myosin-like amino terminal half (15, 16) . Specific myocilin mutants that lack a PTS1 signal (e.g. Q368X) may interact indirectly with PTS1R by oligomerization with WT myocilin and exposure of the normally cryptic WT myocilin PTS1 signal. This interaction between WT myocilin, Q368X myocilin and PTS1R was seen in the co-immunoprecipitation experiments ( Fig. 2A ).
Mutant myocilin localizes to peroxisomes in human TM cells
Myocilin appears to be a stress response protein (17) , and the expression of endogenous WT myocilin was upregulated by transfection of TM5 cells (data not shown). This allowed us to examine the mutation-dependent co-localization of myocilin with peroxisomes. TM cells cotransfected with EGFP-PTS1 and WT or mutant myocilin tagged on the C-terminus with DsRed showed mutation-dependent co-localization of DsRed and EGFP fluorescence ( Fig. 3A -D) . WT myocilin was not co-localized with peroxisomes ( Fig. 3A) . DsRed tagged WT myocilin was secreted by transfected TM cells, similar to un-tagged WT myocilin (data not shown). Therefore, the intracellular levels of WT myocilin were less than that for mutant myocilins, which were not secreted. The less severe Q368X (MYOC367-DsRed) mutation showed only modest co-localization with peroxisomes (Fig. 3B) . In contrast, the more severe MYOC mutants G364V (G364V MYOC504-DsRed) and Y437H (Y437H MYOC504-DsRed) showed increased co-localization with peroxisomes ( Fig. 3C  and D) . The co-localization of mutant myocilin with peroxisomes was even more apparent and unambiguous when examining 3D wide field deconvolution images of the transfected cells. The myocilin-DsRed constructs have internalized, or are missing (MYOC367-DsRed) the myocilin C-terminal PTS1 sequence (SKM). Therefore, any co-localization of myocilin with peroxisomes is due to the indirect interaction of endogenous TM cell WT myocilin with mutant myocilin exposing the cryptic WT myocilin PTS1 site.
Myocilin C-terminal PTS1 is required to elevate IOP in mice
To determine whether the myocilin-PTS1R interaction and subsequent peroxisomal localization is necessary for pathogenesis, we evaluated the effects of intravitreal injection of human MYOC expression vectors on mouse IOP. Ad5 expression vectors efficiently transduce TM cells (18) . We therefore used Ad5 vectors to express WT or mutant myocilin in individual mouse eyes. Injection of MYOCWT adenovirus had no effect on IOP (Fig. 4A) . Likewise, MYOCQ368X (Fig. 4B ) and MYOCS502P (Fig. 4D) adenovirus, that lack the PTS1 site, did not elevate IOP. In contrast, injection of MYOCY437H (Fig. 4F) or MYOCG364V (Fig. 4E ) mutants significantly elevated IOP (P , 0.01). Changing the PTS1 site in the human Y437H mutant to the mouse LEM sequence (MYOCY437H.LEM ), which is no longer a PTS1 site (Fig. 2C) , prevented IOP induction (Fig. 4G) . Although injection of MYOCQ368X alone had no effect on IOP (Fig. 4B) , co-injection of both MYOCWT and MYOCQ368X expression vectors elevated IOP (P , 0.001) (Fig. 4C ).
DISCUSSION
Elevated IOP in MYOC glaucoma is a gain-of-function phenotype based on several lines of evidence (5 -9). WT myocilin is a secreted multimeric glycoprotein synthesized in the ER-Golgi pathway (10,19 -22) . In vitro data have shown that myocilin containing glaucomatous mutations is not secreted from TM cells (10), forms heteromultimers that can diminish WT secretion (10) , is detergent insoluble (11) , is misfolded and retained in the ER (12) and may be retrotranslocated to the cytosol for ubiquitination and proteasomal degradation (23) .
We have identified an unexpected binding partner, PTS1R, for misfolded myocilin. PTS1R was identified by yeast twohybrid analysis using TM or heart cell cDNA libraries as binding partners with C-terminal half WT or mutant myocilin (Fig. 1B and C) , and this interaction was confirmed by mammalian two-hybrid analysis (Fig. 1D) . Myocilin itself was not detected in our two-hybrid assays likely due to the inefficiency of large multimeric myocilin to enter the nucleus, which is required for detection in two-hybrid assays. Co-immunoprecipitation studies showed that mutant myocilin interacts either directly (e.g. Y437H, G364V mutants) or indirectly (e.g. Q368X mutant) with PTS1R via mutation-induced misfolding and exposure of the normally cryptic C-terminal PTS1 sequence (SKM) in human myocilin (Fig. 2) . Our co-immunoprecipitation data also suggest that early onset, severe myocilin mutants such as Y437H interact with PTS1R more effectively than later onset, milder myocilin mutants such as Q368X. Evidence for PTS1R shuttling of mutant myocilin to peroxisomes was seen by direct visualization of fluorescent protein-tagged myocilin and PTS1 in TM cells (Fig. 3) .
The expression of human mutant myocilin in the eyes of mice caused the relevant glaucoma phenotype of elevated IOP, and the degree of IOP elevation was mutation specific (Fig. 4) . In our previous studies, injection of certain, specific adenoviral vectors either intracamerally or intravitreally affected IOP in mice. However, intravitreal injection, as done in this study, typically produced a more pronounced and consistent response. We speculate that the vitreous serves as a depot for the vector resulting in a slow release and longer duration of transduction. Studies using an adenoviral vector encoding the green fluorescence protein (GFP) as a reporter gene delivered by intravitreal injection induced expression of GFP mainly in TM cells, with much lower expression in some anterior iris epithelial cells, corneal endothelial cells and rarely in the lens epithelium (data not shown). Injection of adenovirus expressing MYOC mutations, G364V (Fig. 4E) and Y437H (Fig. 4F ) caused significant IOP elevation, whereas WT MYOC did not (Fig. 4A) . Constructs that lacked the PTS1 signal, including Q368X (Fig. 4B) , S502P (Fig. 4D ) and Y437H-LEM (Fig. 4G) , also had no effect on IOP. Although transduction with Q368X did not elevate IOP, support for indirect interaction of mutant myocilin with PTS1R was shown by the WT þ Q368X co-infection, where only the two viruses expressed together caused elevated IOP (Fig. 4C versus A and B) . Of the myocilin orthologs identified to date, mouse, cat and rat are not predicted to encode peroxisomal targeting signals on their C-terminus (Fig. 2C) (24) . Therefore, substituting the human C-terminus (SKM) with the mouse myocilin C-terminus (LEM) in the Y437H-LEM mutant (Fig. 4G) showed that the human C-terminus is necessary for IOP elevation. Mutation of the human C-terminal SKM to PKM (S502P mutant) also verified the importance of the human C-terminal PTS1 for IOP elevation. S502P is the myocilin variant reported in a British family with juvenile open angle glaucoma (25) and is not secreted from transfected TM cells using a western blot assay previously shown to distinguish pathogenic from nonpathogenic myocilin polymorphisms (data not shown) (10), supporting S502P as a disease-causing mutation. The lack of a PTS1 signal on mouse myocilin explains why IOP was unchanged in mice overexpressing mouse WT myocilin (7) and in knock-in mice expressing the mouse ortholog of human Y437H myocilin (9) . These data support a unique gain-of-function role for MYOC glaucoma contingent on the interaction of mutant human myocilin with PTS1R. Lack of glaucoma seen by Zillig et al. (26) in mice expressing human Y437H myocilin is likely due to the lens-targeted expression and retention of mutant myocilin within the lens. Based on our results, transgenic mice expressing human mutant myocilin in the aqueous outflow pathway may prove a valuable model of human glaucoma.
There is a phenotype -genotype correlation for many of the glaucomatous MYOC mutations (4). In our study, interaction of mutant myocilin with PTS1R and the degree of IOP elevation in MYOC transduced mouse eyes correlated well with the clinical IOP phenotypes of MYOC glaucoma patients. WT myocilin is secreted from TM cells and is found in the aqueous humor. In contrast, mutant myocilin is misfolded, retained in the ER and not secreted from TM cells. Within the ER, misfolded myocilin is likely recognized by the ERAD pathway and dislocated to the cytoplasm for ubiquination and proteosome mediated degradation. However, exposure of the normally cryptic PTS1 signal in mutants would allow interaction of myocilin with PTS1R (Fig. 5) . Therefore, there is likely to be competition between ubiquitin-proteasome degradation and PTS1R interaction of the mutant myocilin proteins. Several mechanisms may be responsible for the mutation specific interaction with PTS1R and degree of IOP elevation. Myocilin normally exists as homodimers and higher order multimers, which in MYOC glaucoma patients would lead to WT myocilin-mutant myocilin heterodimers. Interaction of WT myocilin with the misfolded mutant myocilin may or may not expose the normally cryptic PTS1 signal on WT myocilin. The higher degree of interaction between Y437H myocilin and PTS1R may be due to exposure of the cryptic PTS1 sites on both the mutant and WT myocilin molecules, essentially doubling the chance for binding PTS1R. Other MYOC mutations may expose the PTS1 site only on the mutant myocilin molecule. Interaction of WT myocilin with mutant myocilin proteins that lack a PTS1 site (S502P, Q368X) may expose the cryptic signal on WT myocilin (Fig. 5) . These latter two scenarios may lead to weaker interactions with PTS1R. In addition, specific myocilin mutations may lead to varying degrees of myocilin misfolding, some of which are better recognized by the ubiquitin-proteasome degradation pathway causing decreased opportunity to interact with PTS1R and a milder IOP phenotype.
Accumulation of misfolded mutant myocilin within cells may lead to activation of the unfolded protein response (UPR) or segregation of misfolded myocilin into aggresomes. Y437H or G364V) with an exposed PTS1 motif, is synthesized and oligomerized in the ER, retro-translocated from the ER into the cytosol, and either ubiquitylated and degraded by the proteosome or bound by PTS1R and shuttled to the peroxisome. Misfolded mutant myocilin that lacks the PTS1 motif (e.g. Q368X or S502P), associates by heteroligomerization with WT myocilin causing misfolding and exposure of its partner WT myocilin PTS1 motif.
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Several reports (12, 23) , as well as our own research, suggest that mutant myocilin does not form the classical aggresomes as often seen in neurodegenerative conformational disorders such as Huntington's, Alzheimer's and Parkinson's disease (27) . Alternatively, the intracellular accumulation of mutant myocilin may cause ER stress and induction of UPR. Mice expressing mutant mouse myocilin did not develop elevated IOP and did not have activated UPR despite non-secretion of myocilin (9) . However, transduction of cultured TM cells with mutant human myocilin caused ER stress and TM dysfunction (12) , suggesting that in addition to or in response to dislocation of mutant human myocilin to peroxisomes, ER stress may play a role in the pathogenic process. The abnormal accumulation of misfolded protein may also impair the ubiquitin -proteasome system (28), resulting in a viscous cycle of protein accumulation and ER stress. In summary, these experiments identify a novel mechanism for IOP elevation in glaucoma. Our results are the first to explain why mutations in human but not mouse MYOC cause IOP elevation. We show that mutations in human MYOC induce exposure of a cryptic peroxisomal targeting sequence whose interaction with the PTS1R is necessary for IOP elevation. Importantly, mutants that lead to stronger interactions with the PTS1R induced earlier and more severe IOP elevation compared to more weakly interacting mutants. This is the first disease-gene-based mouse model of human POAG that may be useful for the further dissection and understanding of glaucoma pathophysiology. Mutation-induced exposure of a cryptic signaling site in a protein may be a more general event in gain-of-function diseases than is currently recognized.
MATERIALS AND METHODS
Constructs for mammalian cell expression
Plasmid pEGFP.SKL was constructed essentially as described (29) . Myocilin mutants G364V, Q368X, K398R, Y437H and S502P were created from WT myocilin in the pcDNA3 vector (Invitrogen, Carlsbad, CA, USA), as previously described (10) . DsRed-tagged myocilin was created by subcloning WT or mutant myocilin from pcDNA3.MYOC into pDsRed-N1 (Clontech, Palo Alto, CA, USA). DsRed-tagged mutant myocilin was created using Stratagene Quick Change Mutagenesis (Stratagene, Cedar Creek, Texas, USA). The MYOC367-DsRed fusion was created by replacing the WT MYOC504DsRed sequence with an amplified fragment containing amino acids 1 -367 from the Q368X mutant with an additional BamH1 site incorporated to allow inframe fusion with DsRed. All clones were verified by restriction digestion and sequencing.
Cell culture
Human TM5 cells were cultured as previously described (30) . COS-7 cells were maintained in DMEM (ATCC, Manassas, VA, USA). All cells were supplemented with 10% FBS (Hyclone, Logan, UT, USA), 100 units/ml Penicillin G, 100 mg/ml Streptomycin sulfate, 2 mm L-glutamine (Invitrogen) and incubated in a humidified 5% CO 2 atmosphere at 378C.
Yeast two-hybrid analysis
Human heart and TM yeast two-hybrid cDNA libraries were screened with human MYOC cDNA clones using the Proquest TM Y2H system (Life Technologies, Rockville, MD, USA). The TM cDNA library was constructed by Life Technologies from a pool of 22 TM cell lines. False positives were controlled in this assay by using four phenotypes for selecting interacting proteins: HIS3 and URA3, cell growth on histidine-or uracil-lacking plates; URA3, conversion of non-toxic 5-fluoroorotic acid to toxic 5-fluoroacil; and lacZ, blue color when assayed with X-gal.
Mammalian two-hybrid analysis
The CheckMate TM mammalian two-hybrid system (Promega, Madison, WI, USA) was used according to the manufacturer's directions. pACT and pBIND plasmids were altered by insertion of a single nucleotide upstream of the Sal1 site in order to facilitate direct, in-frame subcloning of the Y2H clones. These altered plasmids were termed pACTþ1 and pBINDþ1. Fulllength WT myocilin, N-terminal 1-367, and mutant C-terminal half Y437H or S502P constructs were tagged on their N-terminus with the yeast GAL4 DNA binding domain (DBD; amino acids 1 -147) in the pBINDþ1 vector. PTS1RS_N163 (clone A1.1 encoding N-terminal truncated PTS1RS) was fused to the C-terminus of the herpes simplex virus VP16 AD (amino acids 411 -456) in the pACTþ1 vector. Vectors pBIND-Id and pACT-MyoD, supplied in the kit, were used as positive controls. Empty pBIND and pACT vectors were used as negative controls. Control or test pBIND and pACT plasmids were cotransfected into Cos7 cells along with pG5luc and assayed for firefly and renilla luciferase expression using the Dual-Luciferase Reporter Assay System (Promega) and a Turner-TD20/20 luminometer (Turner Instruments). Firefly luciferase activity was normalized to Renilla luciferase activity expressed from the pBIND plasmid.
Co-immunoprecipitation and immunobloting
TM5 cells were transiently transfected with Lipofectamine 2000 (Invitrogen) and various plasmids. Cells were harvested 48 h after transfection and lysed in M-PER (Pierce, Rockford, IL, USA) buffer containing protease inhibitors (Complete TM mini protease inhibitor cocktail, Roche, Mannheim, Germany). Protein concentrations in all lysates were determined using a Coomassie Plus protein assay (Pierce). Immunoprecipitation was performed with 80 mg protein and either anti-VP16 agarose or anti-myocilin antibody 3.1 (21), respectively. Myocilin-antibody complexes were collected with Protein A Sepharose (Pharmacia), precipitates washed, sizefractionated on a 10% NuPage gel (Invitrogen) using MOPS buffer, and transferred to Immobilon-P PVDF (Amersham Biosciences, Piscataway, NJ, USA). Membranes were blocked with 2.7% gelatin in PBS for 2 h at RT. Blots were probed with either rabbit polyclonal anti-PTS1R antisera raised against a 45-kDa C-terminal PTS1R fragment (1 : 5000; gift of Dr Suresh Subramani, UCSD) (31) 
Adenovirus preparation
Plasmids expressing WT or mutant myocilin were subcloned into the Ad5.RSV.K-N.pA shuttle vector and adenovirus particles prepared by the U. of Iowa Gene Transfer Vector Core (GTVC), as previously described (10) . Each virus was tested by the GTVC for WT revertants and for titer by PCR and A549 plaque assay.
Animal studies
All animals were treated in accordance with the ARVO statement for the Use of Animals in Ophthalmic and Vision Research and all protocols were approved and monitored by the Animal Care and Use Committee of Alcon Research, Ltd. The BALB/c mice (1 -4 months old) (Jackson Laboratories, Bar Harbor, ME, USA) used in this study were housed and handled as described (32) . For adenovirus injections, mice were anesthetized followed by injection through the sclera into the vitreous. Each mouse had one eye injected with an adenovirus (2E7 pfu in 2 ml injection volume, Hamilton microsyringe fitted with sterile 33G needle) while the uninjected contralateral eye served as a control. Each injection was made over the course of 1 min. The needle was then left in place in the vitreous for a further minute before being rapidly withdrawn. Eyes to be injected were randomized and investigators were masked to the identity of the injected adenovirus. IOP measurements were taken in conscious mice using a rebound tonometer as described (32) . IOP measurements were taken 96 h post-injection, to allow for viral gene expression, and then every day until sacrifice. Mice were sacrificed at typical peak IOP on day 7 post-injection.
